Literature DB >> 19670332

Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells.

Anniina Koski1, Maria Rajecki, Kilian Guse, Anna Kanerva, Ari Ristimäki, Sari Pesonen, Sophie Escutenaire, Akseli Hemminki.   

Abstract

BACKGROUND: Rapid clearance of adenoviruses from blood by macrophage lineage cells of the liver and spleen, and binding to platelets, hinder their successful systemic use for cancer gene therapy. Vitamin K dependent coagulation factors are important mediators for the adenovirus liver tropism. Here we aim to determine the effects of coagulation factor, thrombocyte and liver macrophage (Kupffer cell) ablation on biodistribution of serotype 5 adenoviruses in mice with orthotopic breast tumors.
METHODS: Prior to intravenous injection of adenoviruses, mice bearing orthotopic breast tumors were pretreated with warfarin to inhibit vitamin K dependent coagulation factor synthesis, an anti-platelet antibody causing thrombocytopenia or an inhibitor of the Kupffer cell scavenger receptor or their combination. Virus availability in blood after injection was determined from blood samples and transgene expression in tissues analyzed 72 hours afterwards with In Vivo Imaging and luciferase assays.
RESULTS: Warfarin pretreatment reduced gene delivery to liver, spleen and lung. Kupffer cell ablation increased persistence of adenoviruses in blood but didn't affect biodistribution significantly. Depletion of Kupffer cells combined with thrombocytopenia doubled the systemic gene delivery of 5/3 chimeric adenovirus to tumors (p < 0.05). Triple ablation of platelets, Kupffer cells and coagulation factors increased the tumor to liver ratio of systemic adenovirus gene delivery by 81% (p < 0.05).
CONCLUSIONS: Depletion of coagulation factors can reduce transduction of liver, spleen and lung. Kupffer cell depletion is the most feasible method of increasing amount adenovirus in systemic blood flow and in combination with ablation of thrombocytes can increase the transduction of adenovirus to tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19670332     DOI: 10.1002/jgm.1373

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  18 in total

1.  Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy.

Authors:  Joshua J Short; Angel A Rivera; Hongju Wu; Mark R Walter; Masato Yamamoto; J Michael Mathis; David T Curiel
Journal:  Mol Cancer Ther       Date:  2010-08-24       Impact factor: 6.261

2.  Retargeting of gene expression using endothelium specific hexon modified adenoviral vector.

Authors:  Sergey A Kaliberov; Lyudmila N Kaliberova; Zhi Hong Lu; Meredith A Preuss; Justin A Barnes; Cecil R Stockard; William E Grizzle; Jeffrey M Arbeit; David T Curiel
Journal:  Virology       Date:  2013-10-15       Impact factor: 3.616

3.  Adenoviruses with an αvβ integrin targeting moiety in the fiber shaft or the HI-loop increase tumor specificity without compromising antitumor efficacy in magnetic resonance imaging of colorectal cancer metastases.

Authors:  Sergio Lavilla-Alonso; Gerd Bauerschmitz; Usama Abo-Ramadan; Juha Halavaara; Sophie Escutenaire; Iulia Diaconu; Turgut Tatlisumak; Anna Kanerva; Akseli Hemminki; Sari Pesonen
Journal:  J Transl Med       Date:  2010-08-23       Impact factor: 5.531

Review 4.  Advances and future challenges in adenoviral vector pharmacology and targeting.

Authors:  Reeti Khare; Christopher Y Chen; Eric A Weaver; Michael A Barry
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

5.  Tropism-modification strategies for targeted gene delivery using adenoviral vectors.

Authors:  Lynda Coughlan; Raul Alba; Alan L Parker; Angela C Bradshaw; Iain A McNeish; Stuart A Nicklin; Andrew H Baker
Journal:  Viruses       Date:  2010-10-13       Impact factor: 5.818

6.  Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus.

Authors:  Y-P Liu; C Tong; A Dispenzieri; M J Federspiel; S J Russell; K-W Peng
Journal:  Cancer Gene Ther       Date:  2011-11-25       Impact factor: 5.987

Review 7.  Oncolytic virotherapy.

Authors:  Stephen J Russell; Kah-Whye Peng; John C Bell
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

8.  SR-A and SREC-I are Kupffer and endothelial cell receptors for helper-dependent adenoviral vectors.

Authors:  Pasquale Piccolo; Francesco Vetrini; Pratibha Mithbaokar; Nathan C Grove; Terry Bertin; Donna Palmer; Philip Ng; Nicola Brunetti-Pierri
Journal:  Mol Ther       Date:  2013-01-29       Impact factor: 11.454

9.  Mutation of the fiber shaft heparan sulphate binding site of a 5/3 chimeric adenovirus reduces liver tropism.

Authors:  Anniina Koski; Eerika Karli; Anja Kipar; Sophie Escutenaire; Anna Kanerva; Akseli Hemminki
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

10.  Adrenal gland infection by serotype 5 adenovirus requires coagulation factors.

Authors:  Lucile Tran; Laure-Hélène Ouisse; Peggy Richard-Fiardo; Philippe R Franken; Jacques Darcourt; Gaétan Cornilleau; Karim Benihoud; Georges Vassaux
Journal:  PLoS One       Date:  2013-04-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.